• Product name

  • Description

    Rabbit polyclonal to NLRP1
  • Host species

  • Tested applications

    Suitable for: IHC-P, WB, ICC/IFmore details
  • Species reactivity

    Reacts with: Human
  • Immunogen

    Synthetic peptide corresponding to NLRP1 (C terminal).

  • Positive control

    • U937 cell lysate.



Our Abpromise guarantee covers the use of ab36852 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
IHC-P Use a concentration of 5 µg/ml. Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.
WB Use a concentration of 1 - 2 µg/ml. Detects a band of approximately 155 kDa (predicted molecular weight: 155 kDa).
ICC/IF Use a concentration of 10 µg/ml.


  • Function

    Able to form cytoplasmic structures termed death effector filaments. Enhances APAF1 and cytochrome c-dependent activation of pro-caspase-9 and consecutive apoptosis. Stimulates apoptosis through activation of caspase-3. Involved in activation of caspase-1 and caspase-5 as part of the NALP1 inflammasome complex which leads to processing and release of IL1B and IL18. Binds ATP.
  • Tissue specificity

    Widely expressed. Isoform 1 and isoform 2 are expressed in peripheral blood leukocytes and chronic myelogenous leukemia cell line K-562, followed by thymus, spleen and heart. Also detected in brain, lung, placenta, small intestine, colon, kidney, liver, muscle, testis and epithelial cells. Absent from hematopoietic progenitor cells but expressed upon differentiation of cells into granulocytes and, to a lesser extent, monocytes. In peripheral blood cells, highest levels are found in T-lymphocytes, granulocytes and monocytes. Expression is significantly increased in bone marrow blast cells of some acute leukemia patients but not in solid tumors.
  • Involvement in disease

    Genetic variations in NLRP1 are associated with susceptibility to vitiligo (VTLG) [MIM:193200]. VTLG is a pigmentary disorder of the skin characterized by circumscribed depigmented macules and patches, commonly on extensor aspects of extremities, on the face or neck and in skin folds. It is a progressive disorder in which some or all of the melanocytes in the affected skin are selectively destroyed. It is a multifactorial disorder with a complex etiology probably including autoimmune mechanisms, and is associated with an elevated risk of other autoimmune diseases.
    Genetic variations in NLRP1 gene are associated with susceptibility to vitiligo-associated multiple autoimmune disease type 1 (VAMAS1) [MIM:606579]. VAMAS1 is an autoimmune disorder characterized by the association of vitiligo with several autoimmune and autoinflammatory diseases including autoimmune thyroid disease, rheumatoid arthritis and systemic lupus erythematosus.
  • Sequence similarities

    Belongs to the NLRP family.
    Contains 1 CARD domain.
    Contains 1 DAPIN domain.
    Contains 6 LRR (leucine-rich) repeats.
    Contains 1 NACHT domain.
  • Cellular localization

    Cytoplasm. Nucleus.
  • Information by UniProt
  • Database links

  • Alternative names

    • CARD 7 antibody
    • CARD7 antibody
    • Caspase recruitment domain protein 7 antibody
    • Caspase recruitment domain-containing protein 7 antibody
    • CLR17.1 antibody
    • Death effector filament forming Ced 4 like apoptosis protein antibody
    • Death effector filament-forming ced-4-like apoptosis protein antibody
    • DEFCAP antibody
    • DEFCAP L/S antibody
    • DKFZp586O1822 antibody
    • KIAA0926 antibody
    • LRR and PYD domains-containing protein 1 antibody
    • NAC alpha/beta/gamma/delta antibody
    • NAC antibody
    • NACHT antibody
    • NACHT leucine rich repeat and PYD containing 1 antibody
    • NACHT leucine rich repeat and PYD pyrin domain containing 1 antibody
    • NACHT leucine rich repeat and pyrin domain containing 1 antibody
    • NACHT LRR and PYD containing protein 1 antibody
    • NALP 1 antibody
    • NALP1 antibody
    • NALP1_HUMAN antibody
    • NLR family pyrin domain containing 1 antibody
    • NLRP 1 antibody
    • NLRP1 antibody
    • NLRP1 protein antibody
    • Nucleotide binding domain and caspase recruitment domain antibody
    • Nucleotide binding oligomerization domain leucine rich repeat and pyrin domain containing 1 antibody
    • Nucleotide-binding domain and caspase recruitment domain antibody
    • PP 1044 antibody
    • PP1044 antibody
    see all


  • Anti-NLRP1 antibody (ab36852) at 2 µg/ml + U937 cell lysate

    Predicted band size: 155 kDa
    Observed band size: 155 kDa

  • IHC image of ab36852 staining in human normal spleen formalin fixed paraffin embedded tissue section, performed on a Leica BondTM system using the standard protocol F. The section was pre-treated using heat mediated antigen retrieval with sodium citrate buffer (pH6, epitope retrieval solution 1) for 20 mins. The section was then incubated with ab36852, 5µg/ml, for 15 mins at room temperature and detected using an HRP conjugated compact polymer system. DAB was used as the chromogen. The section was then counterstained with haematoxylin and mounted with DPX.

    For other IHC staining systems (automated and non-automated) customers should optimize variable parameters such as antigen retrieval conditions, primary antibody concentration and antibody incubation times.

  • Immunofluorescence of NLRP1 in K562 cells using ab36852 at 20 ug/ml.


ab36852 has not yet been referenced specifically in any publications.

Customer reviews and Q&As

There are currently no Customer reviews or Questions for ab36852.
Please use the links above to contact us or submit feedback about this product.

For licensing inquiries, please contact partnerships@abcam.com

Sign up